Applying mass spectrometric methods to study androgen biosynthesis and metabolism in prostate cancer.

Recent development of gas chromatography and liquid chromatography-tandem mass spectrometry (GC-MS/MS, LC-MS/MS) has provided novel tools to define sex steroid concentrations. These new methods overcome several of the problems associated with immunoassays for sex steroids. With the novel MS-based applications we are now able to measure small concentrations of the steroid hormones reliably and with high accuracy in both body fluids and tissue homogenates. The sensitivity of the tandem mass spectrometry assays allows us also for the first time to reliably measure picomolar or even femtomolar concentrations of estrogens and androgens. Furthermore, due to a high sensitivity and specificity of MS technology, we are also able to measure low concentrations of steroid hormones of interest in the presence of pharmacological concentration of other steroids and structurally closely related compounds. Both of these features are essential for multiple preclinical models for prostate cancer. The MS assays are also valuable for the simultaneous measurement of multiple steroids and their metabolites in small sample volumes in serum and tissue biopsies of prostate cancer patients before and after drug interventions. As a result, novel information about steroid hormone synthesis and metabolic pathways in prostate cancer has been obtained. In our recent studies, we have extensively applied a GC-MS/MS method to study androgen biosynthesis and metabolism in VCaP prostate cancer xenografts in mice. In the present review, we shortly summarize some of the benefits of the GC-MS/MS and novel LC-MS/MS assays, and provide examples of their use in defining novel mechanisms of androgen action in prostate cancer.

• Publication year

  2019

• Venue

  Journal of Molecular Endocrinology

• Publication date

  2019-05-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1530/JME-18-0150PMID 30917337
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Adrenals Contribute to Growth of Castration-Resistant VCaP Prostate Cancer Xenografts.

  2018cited by this paper
• Discovery and development of ODM-204: A Novel nonsteroidal compound for the treatment of castration-resistant prostate cancer by blocking the androgen receptor and inhibiting CYP17A1.

  2018cited by this paper
• The Use of 5-Alpha Reductase Inhibitors to Manage Benign Prostatic Hyperplasia and the Risk of All-cause Mortality.

  2018cited by this paper
• Intratumoral androgen levels are linked to TMPRSS2-ERG fusion in prostate cancer.

  2018cited by this paper
• Regulation of masculinization: androgen signalling for external genitalia development

  2018cited by this paper
• A brief history of intracrine androgen metabolism by castration-recurrent prostate cancer.

  2018cited by this paper
• Androgen action in prostate function and disease.

  2018cited by this paper
• Analysis by LC–MS/MS of endogenous steroids from human serum, plasma, endometrium and endometriotic tissue

  2018cited by this paper
• Moving Towards Precision Urologic Oncology: Targeting Enzalutamide-resistant Prostate Cancer and Mutated Forms of the Androgen Receptor Using the Novel Inhibitor Darolutamide (ODM-201).

  2018cited by this paper
• 28PODM-208, a novel CYP11A1-inhibitor as a therapeutic approach for the treatment of castration-resistant prostate cancer

  2017cited by this paper
• Profiling adrenal 11β-hydroxyandrostenedione metabolites in prostate cancer cells, tissue and plasma: UPC2-MS/MS quantification of 11β-hydroxytestosterone, 11keto-testosterone and 11keto-dihydrotestosterone.

  2017cited by this paper
• Steroidogenesis: Unanswered Questions.

  2017cited by this paper
• The in vitro metabolism of 11β-hydroxyprogesterone and 11-ketoprogesterone to 11-ketodihydrotestosterone in the backdoor pathway.

  2017cited by this paper
• Intracrine androgen biosynthesis, metabolism and action revisited

  2017cited by this paper
• Stem cells and the role of ETS transcription factors in the differentiation hierarchy of normal and malignant prostate epithelium.

  2017cited by this paper
• Circulating steroid hormone variations throughout different stages of prostate cancer.

  2017cited by this paper
• Reprint of "Steroid 5α-reductase 2 deficiency".

  2017cited by this paper
• Direct Metabolic Interrogation of Dihydrotestosterone Biosynthesis from Adrenal Precursors in Primary Prostatectomy Tissues

  2017cited by this paper
• The art of measuring steroids: Principles and practice of current hormonal steroid analysis.

  2017cited by this paper
• Mass spectrometry, immunoassay and valid steroid measurements in reproductive medicine and science.

  2017cited by this paper
• The steroid metabolite 16(β)-OH-androstenedione generated by CYP21A2 serves as a substrate for CYP19A1.

  2017cited by this paper
• Simultaneous quantitation of nine hydroxy-androgens and their conjugates in human serum by stable isotope dilution liquid chromatography electrospray ionization tandem mass spectrometry.

  2017cited by this paper
• Androgen synthesis in prostate cancer: do all roads lead to Rome?

  2017cited by this paper
• LuCaP Prostate Cancer Patient‐Derived Xenografts Reflect the Molecular Heterogeneity of Advanced Disease and Serve as Models for Evaluating Cancer Therapeutics

  2017cited by this paper
• The use of 5-alpha reductase inhibitors in the treatment of benign prostatic hyperplasia

  2017cited by this paper
• 11-Ketotestosterone and 11-Ketodihydrotestosterone in Castration Resistant Prostate Cancer: Potent Androgens Which Can No Longer Be Ignored

  2016cited by this paper
• 11-Ketotestosterone Is a Major Androgen Produced in Human Gonads.

  2016cited by this paper
• Adrenal-derived 11-oxygenated 19-carbon steroids are the dominant androgens in classic 21-hydroxylase deficiency.

  2016cited by this paper
• Inflammation, dysregulated metabolism and aromatase in obesity and breast cancer.

  2016cited by this paper
• Sex hormone-binding globulin regulation of androgen bioactivity in vivo: validation of the free hormone hypothesis

  2016cited by this paper
• Antiandrogens Reduce Intratumoral Androgen Concentrations and Induce Androgen Receptor Expression in Castration-Resistant Prostate Cancer Xenografts.

  2016cited by this paper
• Can LC and LC-MS ever replace immunoassays?

  2016cited by this paper
• Classical and Non-Classical Roles for Pre-Receptor Control of DHT Metabolism in Prostate Cancer Progression

  2016cited by this paper
• Androgen receptor signaling in castration-resistant prostate cancer: a lesson in persistence.

  2016cited by this paper
• Phase 2 Study of the Safety and Antitumor Activity of Apalutamide (ARN-509), a Potent Androgen Receptor Antagonist, in the High-risk Nonmetastatic Castration-resistant Prostate Cancer Cohort

  2016cited by this paper
• Effective Use of Mass Spectrometry in the Clinical Laboratory.

  2016cited by this paper
• Development of a multi-class steroid hormone screening method using Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS)

  2016cited by this paper
• A Phase II, Randomized, Open-Label Study of Neoadjuvant Degarelix versus LHRH Agonist in Prostate Cancer Patients Prior to Radical Prostatectomy

  2016cited by this paper
• Discovery of ODM-201, a new-generation androgen receptor inhibitor targeting resistance mechanisms to androgen signaling-directed prostate cancer therapies

  2015cited by this paper
• Mass spectrometric analysis of steroids: all that glitters is not gold

  2015cited by this paper
• 11β-Hydroxyandrostenedione: Downstream metabolism by 11βHSD, 17βHSD and SRD5A produces novel substrates in familiar pathways.

  2015cited by this paper
• ERG/AKR1C3/AR Constitutes a Feed-Forward Loop for AR Signaling in Prostate Cancer Cells

  2015cited by this paper
• A rapid and sensitive UPLC-MS/MS method for the simultaneous quantification of serum androsterone glucuronide, etiocholanolone glucuronide, and androstan-3α, 17β diol 17-glucuronide in postmenopausal women.

  2015cited by this paper
• The DHEA-sulfate depot following P450c17 inhibition supports the case for AKR1C3 inhibition in high risk localized and advanced castration resistant prostate cancer.

  2015cited by this paper
• Measurement of a Comprehensive Sex Steroid Profile in Rodent Serum by High-Sensitive Gas Chromatography-Tandem Mass Spectrometry.

  2015cited by this paper
• 2β- and 16β-hydroxylase activity of CYP11A1 and direct stimulatory effect of estrogens on pregnenolone formation.

  2015cited by this paper
• Mass spectrometry and immunoassay: how to measure steroid hormones today and tomorrow.

  2015cited by this paper
• Management of subclinical hypothyroidism in pregnancy: are we too simplistic?

  2015cited by this paper
• The aldo-keto reductases (AKRs): Overview.

  2015cited by this paper
• Conversion of abiraterone to D4A drives antitumor activity in prostate cancer

  2015cited by this paper
• Editorial: the new instructions to authors for the reporting of steroid hormone measurements.

  2014cited by this paper
• Editorial: The new instructions to authors for the reporting of steroid hormone measurements.

  2014cited by this paper
• Androgen dynamics and serum PSA in patients treated with abiraterone acetate

  2014cited by this paper
• Castration induces up-regulation of intratumoral androgen biosynthesis and androgen receptor expression in an orthotopic VCaP human prostate cancer xenograft model.

  2014cited by this paper
• Roles for the Backdoor Pathway of Androgen Metabolism in Prostate Cancer Response to Castration and Drug Treatment

  2014cited by this paper
• A tale of two trials: The impact of 5α-reductase inhibition on prostate cancer (Review)

  2014cited by this paper
• In vitro and in vivo characterisation of ASP9521: a novel, selective, orally bioavailable inhibitor of 17β-hydroxysteroid dehydrogenase type 5 (17βHSD5; AKR1C3)

  2014cited by this paper
• Activity and safety of ODM-201 in patients with progressive metastatic castration-resistant prostate cancer (ARADES): an open-label phase 1 dose-escalation and randomised phase 2 dose expansion trial.

  2014cited by this paper
• Editorial: The new instructions to authors for the reporting of steroid hormone measurements.

  2014cited by this paper
• Case for the wider adoption of mass spectrometry-based adrenal steroid testing, and beyond.

  2014cited by this paper
• Intense androgen-deprivation therapy with abiraterone acetate plus leuprolide acetate in patients with localized high-risk prostate cancer: results of a randomized phase II neoadjuvant study.

  2014cited by this paper
• Androgen biosynthesis in castration-resistant prostate cancer.

  2014cited by this paper
• Steroidogenic Enzyme AKR1C3 Is a Novel Androgen Receptor-Selective Coactivator that Promotes Prostate Cancer Growth

  2013cited by this paper
• Development, validation and application of a stable isotope dilution liquid chromatography electrospray ionization/selected reaction monitoring/mass spectrometry (SID-LC/ESI/SRM/MS) method for quantification of keto-androgens in human serum.

  2013cited by this paper
• 11β-Hydroxydihydrotestosterone and 11-ketodihydrotestosterone, novel C19 steroids with androgenic activity: a putative role in castration resistant prostate cancer?

  2013cited by this paper
• 11β-Hydroxyandrostenedione Returns to the Steroid Arena: Biosynthesis, Metabolism and Function

  2013cited by this paper
• Abiraterone in metastatic prostate cancer without previous chemotherapy.

  2013cited by this paper
• Human cytochromes P450 in health and disease

  2013cited by this paper
• Requirement for mass spectrometry sex steroid assays in the Journal of Clinical Endocrinology and Metabolism.

  2013cited by this paper
• LC-MS analysis of estradiol in human serum and endometrial tissue: Comparison of electrospray ionization, atmospheric pressure chemical ionization and atmospheric pressure photoionization.

  2013cited by this paper
• Re: Abiraterone in metastatic prostate cancer without previous chemotherapy.

  2013cited by this paper
• Androgen deprivation promotes intratumoral synthesis of dihydrotestosterone from androgen metabolites in prostate cancer

  2013cited by this paper
• 11β-hydroxyandrostenedione, the product of androstenedione metabolism in the adrenal, is metabolized in LNCaP cells by 5α-reductase yielding 11β-hydroxy-5α-androstanedione.

  2013cited by this paper
• Internal standards in the quantitative determination of protein biopharmaceuticals using liquid chromatography coupled to mass spectrometry.

  2012cited by this paper
• ARN-509: a novel antiandrogen for prostate cancer treatment.

  2012cited by this paper
• Overexpression of aldo-keto reductase 1C3 (AKR1C3) in LNCaP cells diverts androgen metabolism towards testosterone resulting in resistance to the 5α-reductase inhibitor finasteride.

  2012cited by this paper
• Activation of the androgen receptor by intratumoral bioconversion of androstanediol to dihydrotestosterone in prostate cancer.

  2011cited by this paper
• Urine Steroid Metabolomics as a Biomarker Tool for Detecting Malignancy in Adrenal Tumors

  2011cited by this paper
• Steroidogenic Enzymes and Stem Cell Markers Are Upregulated during Androgen Deprivation in Prostate Cancer

  2011cited by this paper
• The use of 5α-reductase inhibitors for the prevention and treatment of prostate cancer.

  2011cited by this paper
• Fast and sensitive liquid chromatography-mass spectrometry assay for seven androgenic and progestagenic steroids in human serum.

  2011cited by this paper
• Dihydrotestosterone synthesis bypasses testosterone to drive castration-resistant prostate cancer

  2011cited by this paper
• Potential Prostate Cancer Drug Target: Bioactivation of Androstanediol by Conversion to Dihydrotestosterone

  2011cited by this paper
• Intratumoral de novo steroid synthesis activates androgen receptor in castration-resistant prostate cancer and is upregulated by treatment with CYP17A1 inhibitors.

  2011cited by this paper
• Inhibitors of type 5 17β-hydroxysteroid dehydrogenase (AKR1C3): overview and structural insights.

  2011cited by this paper
• Abiraterone and increased survival in metastatic prostate cancer.

  2011cited by this paper
• 5αDH‐DOC (5α‐dihydro‐deoxycorticosterone) activates androgen receptor in castration‐resistant prostate cancer

  2010cited by this paper
• Gas chromatography/mass spectrometry (GC/MS) remains a pre-eminent discovery tool in clinical steroid investigations even in the era of fast liquid chromatography tandem mass spectrometry (LC/MS/MS)

  2010cited by this paper
• Development and validation of a sensitive liquid chromatography-tandem mass spectrometry assay to simultaneously measure androgens and estrogens in serum without derivatization.

  2009cited by this paper
• History of aromatase: saga of an important biological mediator and therapeutic target.

  2009cited by this paper
• Importance of using highly pure internal standards for successful liquid chromatography/tandem mass spectrometric bioanalytical assays.

  2009cited by this paper
• Development of a Second-Generation Antiandrogen for Treatment of Advanced Prostate Cancer

  2009cited by this paper
• Medium- and short-chain dehydrogenase/reductase gene and protein families

  2008cited by this paper
• Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth.

  2008cited by this paper
• Androgen biosynthetic pathways in the human prostate.

  2008cited by this paper
• Medium- and short-chain dehydrogenase/reductase gene and protein families

  2008cited by this paper
• Aldo-keto reductases and bioactivation/detoxication.

  2007cited by this paper
• Delay of postnatal maturation sensitizes the mouse prostate to testosterone-induced pronounced hyperplasia: protective role of estrogen receptor-beta.

  2007cited by this paper
• SDR-type human hydroxysteroid dehydrogenases involved in steroid hormone activation.

  2007cited by this paper
• Human aldo-keto reductases: Function, gene regulation, and single nucleotide polymorphisms.

  2007cited by this paper

• Mass Spectrometry Analysis for Clinical Applications: A Review

  2023cites this paper
• Targeting sex steroid biosynthesis for breast and prostate cancer therapy

  2023cites this paper
• CYP19A1 is downregulated by BRD4 and suppresses castration-resistant prostate cancer cell invasion and proliferation by decreasing AR expression.

  2023cites this paper
• The androgen receptor.

  2023cites this paper
• CYP19A1 Is Regulated by BRD4 and Suppresses Castration-resistant Prostate Cancer Cell Invasion and Proliferation by Decreasing AR Expression

  2022cites this paper
• Comprehensive Sex Steroid Profiling in Multiple Tissues Reveals Novel Insights in Sex Steroid Distribution in Male Mice

  2022cites this paper
• Genome-wide crosstalk between steroid receptors in breast and prostate cancers

  2021cites this paper
• Effects of dutasteride in a rat model of chemically induced prostatic inflammation—Potential role of estrogen receptor β

  2020cites this paper
• Steroid Metabolome Analysis in Disorders of Adrenal Steroid Biosynthesis and Metabolism

  2019cites this paper
• The gut microbiota is a major regulator of androgen metabolism in intestinal contents

  2019cites this paper